Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma

This subgroup analysis of the LYM-3002 Phase III study (NCT00722137) investigated whether substituting bortezomib for vincristine in frontline R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy could improve outcomes in East Asian patients with newly diagnosed...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2018-01, Vol.11, p.3869-3882
Main Authors: Jin, Jie, Okamoto, Rumiko, Yoon, Sung-Soo, Shih, Lee-Yung, Zhu, Jun, Liu, Ting, Hong, Xiaonan, Pei, Lixia, Rooney, Brendan, van de Velde, Helgi, Huang, Huiqiang
Format: Article
Language:English
Subjects:
Analysis
Anthracyclines
B cells
Bortezomib
Cancer therapies
Care and treatment
Chemotherapy
Corticosteroids
Cyclophosphamide
Disease
Hematology
Hospitals
Internal medicine
Lymphoma
Medical prognosis
Medicine
Monoclonal antibodies
Multiple myeloma
Non-Hodgkin's lymphomas
Oncology
Original Research
Prednisone
R&D
Research & development
Stem cells
Studies
Targeted cancer therapy
Transplantation
Transplants & implants
University colleges
Vincristine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This subgroup analysis of the LYM-3002 Phase III study (NCT00722137) investigated whether substituting bortezomib for vincristine in frontline R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy could improve outcomes in East Asian patients with newly diagnosed mantle-cell lymphoma (MCL). A total of 121 East Asian patients from China, Taiwan, Japan, and the Republic of Korea with stage II-IV MCL who were ineligible or not considered for stem-cell transplantation were enrolled to six to eight 21-day cycles of R-CHOP or VR-CAP (R-CHOP with bortezomib replacing vincristine). The primary end point was progression-free survival. After a median follow-up of 42.4 months, median progression-free survival in East Asian patients was 13.9 (R-CHOP) versus 28.6 (VR-CAP) months (HR 0.7, =0.157; 43% improvement with VR-CAP). Secondary end points (R-CHOP vs VR-CAP), including complete response rate (47% vs 63%), duration of complete response (median 16.6 vs 46.7 months), and treatment-free interval (median 21 vs 46.5 months), were improved with VR-CAP. VR-CAP was associated with increased but manageable toxicity. The most frequent adverse events were hematologic toxicities. VR-CAP was effective in East Asian patients with newly diagnosed MCL, and could be considered for patients in whom stem-cell transplantation is not an option.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S150339